Vincerx Pharma, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 65.37 million compared to USD 39.31 million a year ago. Basic loss per share from continuing operations was USD 3.11 compared to USD 2.29 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.631 USD | -8.59% | -7.72% | -46.53% |
26/04 | Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday | MT |
26/04 | Vincerx Pharma Prices Public Offering of Shares, Warrants | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.53% | 2.04Cr | |
+11.91% | 11TCr | |
+11.60% | 10TCr | |
-4.68% | 2.38TCr | |
-0.82% | 2.17TCr | |
-10.12% | 1.81TCr | |
-42.12% | 1.63TCr | |
-17.47% | 1.61TCr | |
+2.77% | 1.38TCr | |
+34.58% | 1.18TCr |
- Stock Market
- Equities
- VINC Stock
- News Vincerx Pharma, Inc.
- Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022